Ticagrelor and absorb bioresorbable vascular scaffold implantation for recovery of vascular function after successful chronic total occlusion recanalization.

Trial Profile

Ticagrelor and absorb bioresorbable vascular scaffold implantation for recovery of vascular function after successful chronic total occlusion recanalization.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Dec 2017

At a glance

  • Drugs Ticagrelor (Primary) ; Clopidogrel
  • Indications Arterial occlusive disorders; Coronary disorders
  • Focus Therapeutic Use
  • Acronyms TIGER-BVS
  • Most Recent Events

    • 22 Dec 2017 Status changed from recruiting to active, no longer recruiting.
    • 02 Nov 2017 Primary endpoint (Differences in increase of coronary blood flow (CBF) under adenosine administration in the coronary segment distal to the scaffold implanted immediately after CTO-PCI between the ticagrelor vs. clopidogrel group.) has been met as per the results presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
    • 02 Nov 2017 Results assessing role of Ticagrelor vs. Clopidogrel in improving vascular function presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top